These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24215473)

  • 1. Combating multidrug-resistant Gram-negative bacterial infections.
    Xu ZQ; Flavin MT; Flavin J
    Expert Opin Investig Drugs; 2014 Feb; 23(2):163-82. PubMed ID: 24215473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent progress in development of antibiotics against Gram-negative bacteria].
    Xu ZQ; Xu ZY
    Yao Xue Xue Bao; 2013 Jul; 48(7):993-1004. PubMed ID: 24133966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
    Vergidis PI; Falagas ME
    Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of efflux pump inhibitors to treat Gram-negative infections.
    Blanco P; Sanz-García F; Hernando-Amado S; Martínez JL; Alcalde-Rico M
    Expert Opin Drug Discov; 2018 Oct; 13(10):919-931. PubMed ID: 30198793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New aminoglycoside antibiotics.
    Dozzo P; Moser HE
    Expert Opin Ther Pat; 2010 Oct; 20(10):1321-41. PubMed ID: 20670208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developments on antibiotics for multidrug resistant bacterial Gram-negative infections.
    Voulgaris GL; Voulgari ML; Falagas ME
    Expert Rev Anti Infect Ther; 2019 Jun; 17(6):387-401. PubMed ID: 31006284
    [No Abstract]   [Full Text] [Related]  

  • 8. Will new antimicrobials overcome resistance among Gram-negatives?
    Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metalloenzyme inhibitors for the treatment of Gram-negative bacterial infections: a patent review (2009-2012).
    Supuran CT; Carta F; Scozzafava A
    Expert Opin Ther Pat; 2013 Jul; 23(7):777-88. PubMed ID: 23458841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is in the pipeline for Gram-negative pathogens?
    Talbot GH
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery.
    Schweizer HP
    Expert Opin Drug Discov; 2012 Jul; 7(7):633-42. PubMed ID: 22607346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective.
    Alibert S; N'gompaza Diarra J; Hernandez J; Stutzmann A; Fouad M; Boyer G; Pagès JM
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):301-309. PubMed ID: 27764576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug-resistant gram-negative infections. Bringing back the old.
    Chan-Tompkins NH
    Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers.
    Lam SJ; O'Brien-Simpson NM; Pantarat N; Sulistio A; Wong EH; Chen YY; Lenzo JC; Holden JA; Blencowe A; Reynolds EC; Qiao GG
    Nat Microbiol; 2016 Sep; 1(11):16162. PubMed ID: 27617798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in multidrug-resistant gram-negative bacilli and the role of prolonged β-lactam infusion in the intensive care unit.
    Guervil DJ; Chau T
    Crit Care Nurs Q; 2013; 36(4):345-55. PubMed ID: 24002425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.
    Lomovskaya O; Bostian KA
    Biochem Pharmacol; 2006 Mar; 71(7):910-8. PubMed ID: 16427026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical assessment of colistin in treating infections caused by multidrug-resistant gram-negative bacillus in patients with severe burn].
    Zhang JP; Yang XS; Chen J; Peng YZ; Huang YS
    Zhonghua Shao Shang Za Zhi; 2009 Oct; 25(5):372-6. PubMed ID: 19951562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming multidrug resistance in gram-negative bacteria.
    Poole K
    Curr Opin Investig Drugs; 2003 Feb; 4(2):128-39. PubMed ID: 12669372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.